Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Patent News

Pyrazolo[4,3-H]quinazolines as Cyclin-dependent Kinase Inhibitors for Treating Cancer

Author(s): Surya K. De*

Volume 31, Issue 8, 2024

Published on: 22 June, 2023

Page: [1040 - 1043] Pages: 4

DOI: 10.2174/0929867330666230525160458

Abstract

The application describes the synthesis of 1H-pyrazolo[4,3-H]quinazoline compounds for treating cell proliferation dysfunction and is a broad-spectrum and strongly- active inhibitor for a cell cyclin-dependent kinase (CDK).

Keywords: : Pyrazolo-quinazoline, cyclin-dependent kinase, cancer, inflammation, cell-cycle regulation, cell proliferation.

« Previous Next »
[1]
Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: A changing paradigm. Nat. Rev. Cancer, 2009, 9(3), 153-166.
[http://dx.doi.org/10.1038/nrc2602] [PMID: 19238148]
[2]
Thiel, J.T.; Daigeler, A.; Kolbenschlag, J.; Rachunek, K.; Hoffmann, S. The role of CDK pathway dysregulation and its therapeutic potential in soft tissue sarcoma. Cancers, 2022, 14(14), 3380.
[http://dx.doi.org/10.3390/cancers14143380] [PMID: 35884441]
[3]
Said, M.A.; Abdelrahman, M.A.; Abourehab, M.A.S.; Fares, M.; Eldehna, W.M. A patent review of anticancer CDK2 inhibitors (2017-present). Expert Opin. Ther. Pat., 2017, 32(8), 885-898.
[http://dx.doi.org/10.1080/13543776.2022.2078193]
[4]
Rossi, A.G.; Sawatzky, D.A.; Walker, A.; Ward, C.; Sheldrake, T.A.; Riley, N.A.; Caldicott, A.; Martinez-Losa, M.; Walker, T.R.; Duffin, R.; Gray, M.; Crescenzi, E.; Martin, M.C.; Brady, H.J.; Savill, J.S.; Dransfield, I.; Haslett, C. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat. Med., 2006, 12(9), 1056-1064.
[http://dx.doi.org/10.1038/nm1468] [PMID: 16951685]
[5]
Shi, Z.; Tian, L.; Qiang, T.; Li, J.; Xing, Y.; Ren, X.; Liu, C.; Liang, C. From structure modification to drug launch: A systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple cancer therapy. J. Med. Chem., 2022, 65(9), 6390-6418.
[http://dx.doi.org/10.1021/acs.jmedchem.1c02064] [PMID: 35485642]
[6]
Adon, T.; Shanmugarajan, D.; Kumar, H.Y. CDK4/6 inhibitors: A brief overview and prospective research directions. RSC Advances, 2021, 11(47), 29227-29246.
[http://dx.doi.org/10.1039/D1RA03820F] [PMID: 35479560]
[7]
Xie, Z.; Hou, S.; Yang, X.; Duan, Y.; Han, J.; Wang, Q.; Liao, C. Lessons learned from past cyclin-dependent kinase drug discovery efforts. J. Med. Chem., 2022, 65(9), 6356-6389.
[http://dx.doi.org/10.1021/acs.jmedchem.1c02190] [PMID: 35235745]
[8]
Cetin, B.; Wabl, C.A.; Gumusay, O. CDK4/6 inhibitors: Mechanisms of resistance and potential biomarkers of responsiveness in breast cancer. Future Oncol., 2022, 18(9), 1143-1157.
[http://dx.doi.org/10.2217/fon-2021-0842] [PMID: 35137602]
[9]
Elfgen, C.; Bjelic-Radisic, V. Targeted therapy in HR+ HER2- metastatic breast cancer: Current clinical trials and their implications for CDK4/6 inhibitor therapy and beyond treatment options. Cancers, 2021, 13(23), 5994.
[http://dx.doi.org/10.3390/cancers13235994] [PMID: 34885105]
[10]
Shaikh, J.; Patel, K.; Khan, T. Advances in pyrazole based scaffold as cyclin-dependent kinase 2 inhibitors for the treatment of cancer. Mini Rev. Med. Chem., 2022, 22(8), 1197-1215.
[http://dx.doi.org/10.2174/1389557521666211027104957] [PMID: 34711160]
[11]
Dhakal, A.; Falkson, C.; O’Regan, R.M. Adjuvant cyclin-dependent kinase 4/6 inhibition in hormone receptor–positive breast cancer: One Monarch to rule them all? Cancer, 2021, 127(18), 3302-3309.
[http://dx.doi.org/10.1002/cncr.33650] [PMID: 34047359]
[12]
Mor, S.; Khatri, M. punia, R.; Sindhu, S. Recent progress in anticancer agents incorporating pyrazole scaffold. Mini Rev. Med. Chem., 2022, 22(1), 115-163.
[http://dx.doi.org/10.2174/1389557521666210325115218] [PMID: 33823764]
[13]
Turner, N.C.; Ro, J.; André, F.; Loi, S.; Verma, S.; Iwata, H.; Harbeck, N.; Loibl, S.; Huang Bartlett, C.; Zhang, K.; Giorgetti, C.; Randolph, S.; Koehler, M.; Cristofanilli, M. Palbociclib in hormone-receptor–positive advanced breast cancer. N. Engl. J. Med., 2015, 373(3), 209-219.
[http://dx.doi.org/10.1056/NEJMoa1505270] [PMID: 26030518]
[14]
Burstein, H.J. Systemic therapy for estrogen receptor–positive, HER2-negative breast cancer. N. Engl. J. Med., 2020, 383(26), 2557-2570.
[http://dx.doi.org/10.1056/NEJMra1307118] [PMID: 33369357]
[15]
Hortobagyi, G.N.; Stemmer, S.M.; Burris, H.A.; Yap, Y.S.; Sonke, G.S.; Hart, L.; Campone, M.; Petrakova, K.; Winer, E.P.; Janni, W.; Conte, P.; Cameron, D.A.; André, F.; Arteaga, C.L.; Zarate, J.P.; Chakravartty, A.; Taran, T.; Le Gac, F.; Serra, P.; O’Shaughnessy, J. Overall survival with ribociclib plus letrozole in advanced breast cancer. N. Engl. J. Med., 2022, 386(10), 942-950.
[http://dx.doi.org/10.1056/NEJMoa2114663] [PMID: 35263519]

Rights & Permissions Print Cite
Article Metrics
22
2
Wayfinder Image
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy